BioMarin will be sharing multi-year clinical trial data on valoctocogene roxaparvovec at the upcoming congress of the International Society on Thrombosis and Haemostasis Congress in Melbourne, Australia.
The Victor Grifols Roura Medical Preconference Symposium will take place in Anaheim, CA on October 3rd, 2019
The two companies are looking to combine their proprietary technologies to develop gene therapy candidates for both hemophilia A and B.
The partnership with Bayer and WFH will include a donation of 50 million international units worth of rFVIII therapies to help treat hemophilia A patients in the developing world.
Sigilon and MIT researchers are developing a novel cell therapy designed to control bleeding and to forestall undesired immune responses.
The opening of hemophilia B gene therapy trials to patients with little to no access to conventional treatments would be a pioneering advancement.
The updated trial data shows three individuals with hemophilia B responding well to a one-time treatment with their investigational gene therapy AMT-061.
Senators Baldwin (D-WI) and Jones (D-AL) have introduced the No Junk Plans Act.
Researchers in Iran hope to achieve better outcomes for this vulnerable patient subgroup.
The investigators are working to build on factor VIIa’s established utility to stem bleeding, to one that can also prevent bleeding in both hemophilia A and B patients.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car